

## South East London Area Prescribing Committee

Withdrawal of formulary recommendation number 017 (issued November 2014):

Vedolizumab (Entyvio®) intravenous infusion for the treatment of Crohn's disease (CD) in adults

This formulary recommendation has been withdrawn from local use as it has been superseded by NICE Technology Appraisal Guidance (TAG) number 352: *Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy.* 

The NICE TAG (published August 2015) can be accessed <u>here</u>.

The local SEL IBD pathways can be accessed <u>here</u>

Please contact <u>contactus@selondonics.nhs.uk</u> for further information.

16<sup>th</sup> October 2015